Safety and Feasibility Study of the Shockwave Lithoplasty System

To study the early safety and performance of the Shockwave Medical System in subjects to demonstrate that the device can safely and effectively deliver localized energy for the treatment of vascular disease.

Study Overview

• Status: Completed
• Conditions: Vascular Disease
• Intervention / Treatment: Device: Shockwave System Treatment

Detailed Description

Shockwave Medical, Inc. intends to conduct a prospective, single-arm, single-center, First in Human study designed to evaluate the early safety and feasibility of the Shockwave Lithoplasty System in subjects with heavily calcified infrainguinal arteries with 3.75mm to 6mm reference vessel diameter at target site. The Shockwave Lithoplasty System is indicated to generate sonic shockwave energy within the target treatment site and disrupt calcium within the lesion to allow for subsequent dilation of a peripheral artery stenosis using low balloon pressure. Up to 10 subjects will be enrolled to undergo lihtoplasty.

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Not Applicable

Contacts and Locations

Study Locations

• New Zealand
  • Auckland, New Zealand, 92024
    • Auckland City Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age >18
• Patient or patient's legal representative have been informed of the nature of the study, agrees to participate and has signed the approved consent form.
• Female subjects of childbearing potential have a negative pregnancy test less than 7 days before the procedure.
• Patient is able and willing to comply with all assessments in the study.
• Peripheral arterial disease of Rutherford Category 2, 3, 4, and 5.
• Ability to tolerate an antiplatelet agent (i.e. aspirin, clopidigrel or prasagrel).
• Meets Angiographic Inclusion Criteria

Exclusion Criteria:

• Patients with peripheral arterial disease of Rutherford Category 6.
• Severe or infected gangrene of the lower extremity.
• Planned major amputation.
• Previously implanted stent at the treatment site.
• Patient with an externally-connected intracardiac catheter or pacemaker.
• Patient with an implantable pacemaker or defibrillator.
• Patient has connective tissue disease (e.g., Marfan's syndrome).
• Patient has a hypercoagulable disorder.
• Patient has allergy to imaging contrast media for which they cannot be premedicated.
• Patient is in acute renal failure or chronic renal insufficiency or failure as measured by a serum creatinine of >19.5 µmol/L.
• Patient has active systemic infection.
• Patient has less than a one year life expectancy.
• Patient is pregnant or nursing.
• Patient is participating in another research study involving an investigational agent that has not reached the primary endpoint.
• Patient has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.
• Chronic total occlusion of target vessel.
• Chronic total occlusion of inflow vessel.
• Highly tortuous arteries (bends greater than 30 degrees over the arc length of the balloon)
• Patients requiring concurrent intervention below the most distal target lesion.
• Inflow disease: Stenosis of >50% in vessel proximal to the target lesion which requires treatment with Drug Eluting Balloon (DEB) or atherectomy.
• Prior procedure in target leg within past 3 months.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Lithotripsy Treatment; Shockwave System Treatment -Lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic peripheral arteries.	Device: Shockwave System Treatment; Shockwave System Treatment during vascular disease intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety determined by 30day New-Onset Serious Adverse Events	New Onset Serious Adverse Events (SAE) include death, device-related surgery or repeat hospitalization, occlusion, or major unplanned amputation through 30 days following the procedure.	30 day

Secondary Outcome Measures

Outcome Measure	Time Frame
Angiographic Success as measured by residual stenosis <30% reference vessel.	Peri-Procedural

Collaborators and Investigators

• Sponsor: Shockwave Medical, Inc.
• Investigators: Principal Investigator: Andrew Holden, MD, Auckland City Hospital

Study record dates

Study Major Dates

• Study Start: August 1, 2012
• Primary Completion (Actual): August 1, 2014
• Study Completion (Actual): August 1, 2014

Study Registration Dates

• First Submitted: April 11, 2012
• First Submitted That Met QC Criteria: April 13, 2012
• First Posted (Estimate): April 16, 2012

Study Record Updates

• Last Update Posted (Estimate): August 8, 2014
• Last Update Submitted That Met QC Criteria: August 6, 2014
• Last Verified: August 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases
• Other Study ID Numbers: TD-0047